Vidal Essebag1, Jacqueline Joza2, David H Birnie2, John L Sapp2, Laurence D Sterns2, Francois Philippon2, Raymond Yee2, Eugene Crystal2, Teresa Kus2, Claus Rinne2, Jeffrey S Healey2, Magdi Sami2, Bernard Thibault2, Derek V Exner2, Benoit Coutu2, Chris S Simpson2, Zaev Wulffhart2, Elizabeth Yetisir2, George Wells2, Anthony S L Tang2. 1. From the Division of Cardiology, McGill University Health Centre, Montreal, QC, Canada (V.E., J.J., M.S.); Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada (D.H.B., E.Y., G.W., A.S.L.T.); Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada (J.L.S.); Division of Cardiology, Victoria Cardiac Arrhythmia Trials, Victoria, BC, Canada (L.D.S.); Division of Cardiology, Quebec Heart and Lung Institute, Quebec City, QC, Canada (F.P.); Division of Cardiology, London Health Sciences Centre, London, ON, Canada (R.Y., A.S.L.T.); Division of Cardiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada (E.C.); Division of Cardiology, Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada (V.E., T.K.); Division of Cardiology, St. Mary's General Hospital, Kitchener, ON, Canada (C.R.); Division of Cardiology, Population Health Research Institute, Hamilton, ON, Canada (J.S.H.); Division of Cardiology, Montreal Heart Institute, Montreal, QC, Canada (B.T.); Division of Cardiology, Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada (D.V.E.); Division of Cardiology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada (B.C.); Division of Cardiology, Kingston General Hospital, Kingston, ON, Canada (C.S.S.); and Division of Cardiology, Southlake Regional Health Centre, Newmarket, ON, Canada (Z.W.). vidal.essebag@mcgill.ca. 2. From the Division of Cardiology, McGill University Health Centre, Montreal, QC, Canada (V.E., J.J., M.S.); Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada (D.H.B., E.Y., G.W., A.S.L.T.); Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada (J.L.S.); Division of Cardiology, Victoria Cardiac Arrhythmia Trials, Victoria, BC, Canada (L.D.S.); Division of Cardiology, Quebec Heart and Lung Institute, Quebec City, QC, Canada (F.P.); Division of Cardiology, London Health Sciences Centre, London, ON, Canada (R.Y., A.S.L.T.); Division of Cardiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada (E.C.); Division of Cardiology, Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada (V.E., T.K.); Division of Cardiology, St. Mary's General Hospital, Kitchener, ON, Canada (C.R.); Division of Cardiology, Population Health Research Institute, Hamilton, ON, Canada (J.S.H.); Division of Cardiology, Montreal Heart Institute, Montreal, QC, Canada (B.T.); Division of Cardiology, Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada (D.V.E.); Division of Cardiology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada (B.C.); Division of Cardiology, Kingston General Hospital, Kingston, ON, Canada (C.S.S.); and Division of Cardiology, Southlake Regional Health Centre, Newmarket, ON, Canada (Z.W.).
Abstract
BACKGROUND: The resynchronization-defibrillation for ambulatory heart failure trial (RAFT) study demonstrated that adding cardiac resynchronization therapy (CRT) in selected patients requiring de novo implantable cardiac defibrillators (ICD) reduced mortality as compared with ICD therapy alone, despite an increase in procedure-related adverse events. Data are lacking regarding the management of patients with ICD therapy who develop an indication for CRT upgrade. METHODS AND RESULTS: Participating RAFT centers provided data regarding de novo CRT-D (CRT with ICD) implant, upgrade to CRT-D during RAFT (study upgrade), and upgrade within 6 months after presentation of study results (substudy). Substudy centers enrolled 1346 (74.9%) patients in RAFT, including 644 de novo, 80 study upgrade, and 60 substudy CRT attempts. The success rate (initial plus repeat attempts) was 95.2% for de novo versus 96.3% for study upgrade and 90.0% for substudy CRT attempts (P=0.402). Acute complications occurred among 26.2% of de novo versus 18.8% of study upgrade and 3.4% of substudy CRT implantation attempts (P<0.001). The most common complication was left ventricular lead dislodgement. The principal reasons for not yet attempting upgrade in the substudy were patient preference (31.9%), New York Heart Association Class I (17.0%), and a QRS<150 ms (13.1%). CONCLUSIONS: Among a broad group of implant physicians, CRT upgrades were performed in patients with an ICD in situ with no difference in implant success rate and a reduced acute complication rate as compared with a de novo CRT implant. Decisions to upgrade were influenced by predictors of benefit in subgroup analyses of the RAFT study and other trials.
RCT Entities:
BACKGROUND: The resynchronization-defibrillation for ambulatory heart failure trial (RAFT) study demonstrated that adding cardiac resynchronization therapy (CRT) in selected patients requiring de novo implantable cardiac defibrillators (ICD) reduced mortality as compared with ICD therapy alone, despite an increase in procedure-related adverse events. Data are lacking regarding the management of patients with ICD therapy who develop an indication for CRT upgrade. METHODS AND RESULTS: Participating RAFT centers provided data regarding de novo CRT-D (CRT with ICD) implant, upgrade to CRT-D during RAFT (study upgrade), and upgrade within 6 months after presentation of study results (substudy). Substudy centers enrolled 1346 (74.9%) patients in RAFT, including 644 de novo, 80 study upgrade, and 60 substudy CRT attempts. The success rate (initial plus repeat attempts) was 95.2% for de novo versus 96.3% for study upgrade and 90.0% for substudy CRT attempts (P=0.402). Acute complications occurred among 26.2% of de novo versus 18.8% of study upgrade and 3.4% of substudy CRT implantation attempts (P<0.001). The most common complication was left ventricular lead dislodgement. The principal reasons for not yet attempting upgrade in the substudy were patient preference (31.9%), New York Heart Association Class I (17.0%), and a QRS<150 ms (13.1%). CONCLUSIONS: Among a broad group of implant physicians, CRT upgrades were performed in patients with an ICD in situ with no difference in implant success rate and a reduced acute complication rate as compared with a de novo CRT implant. Decisions to upgrade were influenced by predictors of benefit in subgroup analyses of the RAFT study and other trials.
Authors: Wern Yew Ding; Robert Cooper; Derick Todd; Dhiraj Gupta; Mark Hall; Archana Rao; Jay Wright; Richard Snowdon; Johan Waktare; Simon Modi Journal: J Interv Card Electrophysiol Date: 2018-06-13 Impact factor: 1.900
Authors: Marin Nishimura; Gregory M Marcus; Paul D Varosy; Haikun Bao; Yongfei Wang; Jeptha P Curtis; Jonathan C Hsu Journal: J Interv Card Electrophysiol Date: 2019-04-19 Impact factor: 1.900
Authors: Vaibhav R Vaidya; Roshini Asirvatham; Gurukripa N Kowlgi; Ming-Yan Dai; Jordan J Cochuyt; David O Hodge; Abhishek J Deshmukh; Yong Mei Cha Journal: JACC Clin Electrophysiol Date: 2021-08-25
Authors: Bela Merkely; Annamaria Kosztin; Attila Roka; Laszlo Geller; Endre Zima; Attila Kovacs; Andras Mihaly Boros; Helmut Klein; Jerzy K Wranicz; Gerhard Hindricks; Marcell Clemens; Gabor Z Duray; Arthur J Moss; Ilan Goldenberg; Valentina Kutyifa Journal: Europace Date: 2017-09-01 Impact factor: 5.214
Authors: Mariana Brandão; João Gonçalves Almeida; Paulo Fonseca; Joel Monteiro; Elisabeth Santos; Filipa Rosas; José Nogueira Ribeiro; Marco Oliveira; Helena Gonçalves; João Primo; Ricardo Fontes-Carvalho Journal: Heart Rhythm O2 Date: 2021-12-17
Authors: Naushad A Shaik; Michael Drucker; Christopher Pierce; Gabor Z Duray; Shane Gillett; Crystal Miller; Camden Harrell; George Thomas Journal: J Cardiovasc Electrophysiol Date: 2020-06-01
Authors: Bogdan Beca; John L Sapp; Martin J Gardner; Christopher Gray; Amir AbdelWahab; Ciorsti MacIntyre; Steve Doucette; Ratika Parkash Journal: CJC Open Date: 2019-03-06